Filing Details
- Accession Number:
- 0001179110-15-009895
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-06-16 16:19:42
- Reporting Period:
- 2015-06-15
- Filing Date:
- 2015-06-16
- Accepted Time:
- 2015-06-16 16:19:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 744218 | Celldex Therapeutics Inc. | CLDX | In Vitro & In Vivo Diagnostic Substances (2835) | 133191702 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1255348 | W Avery Catlin | C/O Celldex Therapeutics, Inc. 53 Frontage Road Hampton NJ 08827 | Sr. Vp & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-06-15 | 25,000 | $8.52 | 49,609 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-06-15 | 25,000 | $24.59 | 24,609 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option | Disposition | 2015-06-15 | 25,000 | $0.00 | 25,000 | $8.52 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2010-01-06 | 2019-01-06 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12,2015. The options exercised and sold by the Reporting Person were due to expire January 6,2019.
- 25% of the shares vested on January 6, 2010 and the remainder vested quarterly (in equal amounts) over the subsequent 12 quarters.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.35 to $25.23, inclusive. The Reporting Person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Billionaire Hedge Funds
